Drug intelligence / Profile preview

epaloritovorilil

Development stage: Unknown
Lead developer: The Second Affiliated Hospital of Nanchang University
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Epaloritovorilil is a monoclonal antibody currently under clinical investigation as a second-line systemic therapy for advanced hepatocellular carcinoma (HCC). It is being evaluated in combination with the multi-kinase inhibitor lenvatinib in patients who have either progressed on or are intolerant to prior systemic treatments. The drug is being developed by The Second Affiliated Hospital of Nanchang University, and a prospective, single-arm interventional study (ChiCTR2500113629) has been registered in China to assess its antitumor activity and safety profile in adult patients with advanced HCC.

Other names: epaloritovorilil

Beyond the preview

Go deeper on epaloritovorilil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on epaloritovorilil.

Explore the full profile